The largest healthcare IPO ever

Having trouble seeing the below email? Check here to view it in your browser

High-Growth Health & Pharma Opportunity REVENUE GENERATING Limited Allocation Remaining Find Out More ESTABLISHED PRODUCT RANGE ALREADY IN MARKET   REGISTER TO KNOW MORE   The largest healthcare IPO ever Company Overview Abundant Natural Pharmaceuticals (ANP) is an Australian-based pharmaceutical and nutraceutical platform focused on high-growth magnesium-based health products, including supplements, functional beverages, and therapeutic applications. The business is built on an existing commercial foundation, supported by its distributor and JV partner Abundant Natural Health, which already generates millions in revenue through established retail, pharmacy, and online channels. This provides ANP with an immediate route to market and reduced execution risk. “Magnesium supports over 300 essential biochemical reactions in the body.” — National Institutes of Health New. Innovative. Ready to launch — be part of it. Coming to market soon. Revenue Generating Platform Products already selling across established retail, pharmacy, and online channels with daily-use products driving monthly repeat purchases and subscription-based income. Superior Product Quality & Pipeline Higher concentration of bioavailable magnesium vs typical market products. Scalable pipeline of supplements, liquids, beverages, and therapeutic applications. EcoMag Integration Magnesium sourced via EcoMag (Karratha, Australia) from waste streams, delivering clean, traceable, environmentally responsible production. Backed by Abundant Natural Health with existing infrastructure and customer base. SUSTAINABLE SOURCING CERTIFIED Funding Round LIMITED ALLOCATION TOTAL RAISE (30% EQUITY) USD $1M SECURED USD $500K Minimum Entry: AUD $30,000 The company is expected to scale through revenue and reinvestment, with no ongoing reliance on funding rounds. Investor Returns • Growth-led strategy initially • Dividend distributions targeted from Year 2/3 onward • Strong valuation upside as the platform scales Exit Strategy • IPO (Initial Public Offering) ASX listing as the company grows • Strategic Acquisition (Buyout) Target for global pharmaceutical, nutraceutical, or wellness groups   Summary A rare opportunity combining: Established product range and proven market foundations Scalable, recurring revenue model Strong product differentiation ESG-aligned supply chain Limited capital requirement Clear exit strategies Access Full Investment Details Find Out More CONFIDENTIAL INVESTOR MEMORANDUM AVAILABLE UPON REQUEST In association with © Abundant Natural Pharmaceuticals Pty Limited. All rights reserved.